AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6389217
Drug: Hydrocortisone (Uniderm)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (Uniderm) 1% cream
Trial: 29685482
Drug: Personalized physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized physical therapy
Trial: 20408890
Drug: Complete immunization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete immunization schedule with commercial vaccines
Trial: 17505460
Drug: Corticosteroids administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroids administration (antepartum or postpartum)
Trial: 17505460
Drug: Corticosteroids administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroids administration
Trial: 7881669
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg.kg‐1 in 250 ml 5% dextrose intravenously over 15 min
Trial: 7881669
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in 250 ml 5% dextrose intravenously over 15 min
Trial: 2404433
Drug: Rynatan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rynatan (8 mg chlorpheniramine tannate, 25 mg pyrilamine tannate, 25 mg phenylephrine tannate)
Trial: 39233
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 100 mg Betadrenol daily for three days
Trial: 39233
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 100 mg Betadrenol daily for ten days
Trial: 28202770
Drug: Daptomycin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (5 mg/kg for 12-17 years, 7 mg/kg for 7-11 years, 9 mg/kg for 2-6 years, 10 mg/kg for 12-23 months)
Trial: 28202770
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) treatment (primarily clindamycin or vancomycin)
Trial: 25611207
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg daily for 1 week)
Trial: 22886783
Drug: Elevated CRP
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated CRP (≥2 mg/L)
Trial: 22886783
Drug: No elevated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No elevated CRP (<2 mg/L)
Trial: 19440073
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement (200 mg of testosterone cypionate intramuscular injections every 10 days)
Trial: 25427171
Drug: Zonisamide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (400 mg/d)
Trial: 26623405
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron (Group O)
Trial: 11578887
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide (Group M)
Trial: 11578887
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL normal saline (Group P)
Trial: 7930025
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at concentrations of 100-2000 ppb
Trial: 26008690
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (DAC) alone
Trial: 26008690
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (DAC) in combination with valproic acid (VPA)
Trial: 26008690
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (DAC) in combination with all-trans retinoic acid (ATRA)
Trial: 26008690
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (DAC) in combination with both VPA and ATRA
Trial: 11411653
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine (Nicorette® chewing gum)
Trial: 7911147
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin
Trial: 7911147
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g piperacillin
Trial: 25140958
Drug: Bedaquiline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline (400 mg once daily for 2 weeks, followed by 200 mg three times a week for 22 weeks)
Trial: 20529368
Drug: Comprehensive assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive assessment including in-home interview, self-administered questionnaire, medical/dental examination.
Trial: 9641689
Drug: Low-dose lamifiban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lamifiban (1 microg/min)
Trial: 9641689
Drug: High-dose lamifiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lamifiban (5 microg/min)
Trial: 9641689
Drug: High-dose lamifiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lamifiban and heparin
Trial: 9641689
Drug: Low-dose lamifiban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lamifiban and heparin
Trial: 9641689
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (placebo and heparin)
Trial: 7979888
Drug: Pharmacotherapy (desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (desipramine hydrochloride)
Trial: 28851188
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg orally before PCI and 15 mg/d for 3 days)
Trial: 25389256
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg
Trial: 21612894
Drug: 25 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg/day amikacin
Trial: 21612894
Drug: 30 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg/day amikacin
Trial: 21612894
Drug: 15 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/day (historical standard dose)
Trial: 18848318
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (retinyl palmitate) 0.05% eye drops, four times daily
Trial: 18848318
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A 0.05% eye drops, twice daily
Trial: 16817814
Drug: Cortisol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (0.15 mg/kg)
Trial: 16817814
Drug: Corticosterone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosterone (0.15 mg/kg)
Trial: 16817814
Drug: Corticosterone (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosterone (0.04 mg/kg)
Trial: 11313301
Drug: Intravenous cyclosporine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclosporine, 4 mg x kg(‐1) x day(‐1)
Trial: 11313301
Drug: Methylprednisolone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, 40 mg/day
Trial: 9257745
Drug: Piperacillin plus
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin plus Gentamicin (P+G)
Trial: 8292833
Drug: Commercial Western-style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial Western-style medicine (placebo)
Trial: 29500567
Drug: Target-CF 15
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target-CF 15 g (G1)
Trial: 29500567
Drug: Target-CF 10
RxNorm normalized name: propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target-CF 10 g (G2)
Trial: 12660684
Drug: HeartBar (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HeartBar (3.3 g L-arginine, consumed twice daily for 2 weeks)
Trial: 12660684
Drug: Placebo bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bar (consumed twice daily for 2 weeks)
Trial: 1491124
Drug: Ipriflavone 600
RxNorm normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone 600 mg and 1,000 mg daily (administered in three divided doses)
Trial: 1491124
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (CE) 0.625 mg/day
Trial: 4037631
Drug: 10% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% aqueous solution of povidone-iodine (Betadine)
Trial: 19901117
Drug: Dose-dense epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense epirubicin and cyclophosphamide followed by Paclitaxel (EC/T)
Trial: 16136469
Drug: High-dose vCP1452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vCP1452 (10^8.0 TCID50)
Trial: 16136469
Drug: Regular-dose vCP1452
RxNorm normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular-dose vCP1452 (10^7.26 TCID50)
Trial: 7776501
Drug: Supplementary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary vitamin E intake within the drug group
Trial: 111945
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of xylose
Trial: 111945
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of sodium chloride
Trial: 111945
Drug: Nasal administration
RxNorm normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal administration of small amounts of vasopressin
Trial: 111945
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of sodium chloride with beef-meal
Trial: 31879124
Drug: Booster Immunization
RxNorm normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster Immunization group (BI) - received a single dose of OCV after 3 years
Trial: 31879124
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (Primary Immunization group: PI) - did not receive a booster dose
Trial: 19637104
Drug: Zonisamide 100
RxNorm normalized name: zonisamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 100 mg
Trial: 18041300
Drug: Influenza vaccination
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccination (VAXIGRIP(R) 2003 Southern hemisphere formulation)
Trial: 3545931
Drug: Combined insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined insulin plus sulfonylurea (gliclazide 40 to 240 mg daily for 12 months)
Trial: 3545931
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment only (control group)
Trial: 30850455
Drug: Moisturizers with
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizers with high water: oil ratios (ie, lotions)
Trial: 30850455
Drug: Moisturizers with
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizers with low water:oil content (ie, ointments)
Trial: 24874588
Drug: Surfactant-containing saline
RxNorm normalized name: surfactant protein-D homotrimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant-containing saline solution (group 1)
Trial: 21916358
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gel (CG)
Trial: 21916358
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine spray (CS)
Trial: 21916358
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel (PG)
Trial: 21916358
Drug: placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo spray (PS)
Trial: 16428906
Drug: Concurrent myofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent myofeedback (feedback provided immediately during the trial)
Trial: 15207760
Drug: Cyclic therapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic therapy with etidronate (CTE) - 400 mg/day oral etidronate for 2 weeks followed by 12 weeks of 500 mg/day calcium lactate, repeated every 14 weeks (early-etidronate group)
Trial: 15207760
Drug: Cyclic therapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic therapy with etidronate (CTE) - initiated after 18 months of no treatment (late-etidronate group)
Trial: 11152831
Drug: MULTI-LINK (ML)
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MULTI-LINK (ML) stent
Trial: 9652995
Drug: Testosterone enanthate,
RxNorm normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate, 300 mg, intramuscularly every 3 weeks for 6 months
Trial: 8158680
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A, n = 118)
Trial: 8158680
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A)
Trial: 8158680
Drug: Loco-regional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loco-regional treatment alone (group B, n = 119)
Trial: 8158680
Drug: Loco-regional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loco-regional treatment alone (group B)
Trial: 3045792
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (DZ) 10-15 mg
Trial: 3045792
Drug: Indomethacin (IM)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (IM) 50 mg and 100 mg
Trial: 3045792
Drug: Indomethacin (IM)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (IM) 50 mg and 100 mg + Diazepam (DZ) 10-15 mg
Trial: 30212845
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (two placebo tablets twice a day for 10 days)
Trial: 27760533
Drug: TOBY therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOBY therapy + therapy as usual
Trial: 27760533
Drug: therapy as
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy as usual
Trial: 23001704
Drug: Boceprevir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir 800 mg every 8 hours for 9 days plus a single dose of raltegravir 400 mg on day 10
Trial: 23001704
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg alone
Trial: 16995864
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BIW etanercept for 24 weeks (Study 1)
Trial: 16995864
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BIW etanercept for 12 weeks (Study 2)
Trial: 16995864
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BIW etanercept for 12 weeks (Study 2)
Trial: 16995864
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg QW etanercept for 24 weeks (Study 3)
Trial: 16995864
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BIW etanercept for 24 weeks (Study 3)
Trial: 16995864
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BIW etanercept for 24 weeks (Study 3)
Trial: 11526374
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg IV)
Trial: 3284830
Drug: carbocysteine-sobrerol combination
RxNorm normalized name: carbocysteine / sobrerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbocysteine-sobrerol combination
Trial: 26233732
Drug: Febuxostat 40mg
RxNorm normalized name: FEBUXOSTAT 40MG TAB
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 40mg once daily for 6 months
Trial: 23438800
Drug: Interscalene group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene group (IG) received 30 mL of 0.33% levobupivacaine with adrenalin 1:200,000.
Trial: 23438800
Drug: Selective group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective group (SG) received 15 mL of 0.33% levobupivacaine on each nerve (suprascapular and axillary).
Trial: 12542554
Drug: Vitamin B‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐12 injection treatment
Trial: 10213011
Drug: Irinotecan 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 350 mg/m2
Trial: 7428803
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin (500 mg)
Trial: 7428803
Drug: Oral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ampicillin (500 mg)
Trial: 25548079
Drug: 3 weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 weekly intra‐articular injections of hyaluronic acid (HA)
Trial: 20368393
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg laninamivir octanoate
Trial: 20368393
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg laninamivir octanoate
Trial: 20936975
Drug: oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oseltamivir (75 mg, administered orally twice daily for 5 days)
Trial: 18779299
Drug: Flax oil
RxNorm normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax oil (2.4 g/d)
Trial: 18779299
Drug: Flax oil
RxNorm normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax oil (3.6 g/d)
Trial: 18779299
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (0.6 g/d)
Trial: 18779299
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.2 g/d)
Trial: 18779299
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (1 g/d)
Trial: 7477800
Drug: Combined cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive‐behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)
Trial: 1953053
Drug: Cervagem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervagem (1 mg gemeprost pessary)
Trial: 25391252
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day Pycnogenol®
Trial: 21276217
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program for primary prevention of WMSD (six consecutive weekly sessions)
Trial: 19550287
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal gel (0.001, 0.002, 0.005, or 0.02%)
Trial: 19550287
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal gel (0.02%)
Trial: 19550287
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal gel
Trial: 11431597
Drug: Programmable insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Programmable insulin pump